person · Reporting owner

Rodriguez Susan

Disclosed activity across 5 companies

Tapewire entity: 42060
SEC CIK: 0001812511

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
ARDELYX, INC.ARDX · Entity 4972	Chief Commercial Officer	May 21, 2024	May 23, 2024
HERON THERAPEUTICS, INC. /DE/HRTX · Entity 7133	Director	January 31, 2025	February 04, 2025
Monopar TherapeuticsMNPR · Entity 5152	CCSO	March 02, 2026	March 04, 2026
Veradigm Inc.MDRX · Entity 13670	Director	June 01, 2026	June 03, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

ARDELYX, INC.

Report date May 21, 2024 · Filed May 23, 2024

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	449,092	Reported balance After 2024-05-21 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2024-05-21 · Sale · Disposed 6,703 · Balance 449,092 F1: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. F2: Reflects the adjusted total which includes the purchase of 3,000 shares under the Ardelyx Employee Stock Purchase Plan in February 2024.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes.

F2: Reflects the adjusted total which includes the purchase of 3,000 shares under the Ardelyx Employee Stock Purchase Plan in February 2024.

HERON THERAPEUTICS, INC. /DE/

Report date January 31, 2025 · Filed February 04, 2025 · Amendment

Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	87,180	Reported balance After 2025-01-31 transaction · row 1 Amendment: may correct only part of an earlier disclosure. 1 source row Row 1 · 2025-01-31 · Grant · Acquired 17,950 · Balance 87,180 F1: The shares were granted as restricted stock units which vest in full on January 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.70 · Expires 2035-01-31	Direct	35,900	Reported balance After 2025-01-31 transaction · row 2 Amendment: may correct only part of an earlier disclosure. 1 source row Row 2 · 2025-01-31 · Grant · Acquired 35,900 · Balance 35,900 F2: The stock options vest and become exercisable in 12 equal monthly installments beginning one month after the date of grant.

Filing footnotes · ownership attribution and instrument terms

F1: The shares were granted as restricted stock units which vest in full on January 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock.

F2: The stock options vest and become exercisable in 12 equal monthly installments beginning one month after the date of grant.

Monopar Therapeutics

Report date March 02, 2026 · Filed March 04, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $53.47 · Expires 2036-03-02	Direct	48,728	Reported balance After 2026-03-02 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-03-02 · Grant · Acquired 48,728 · Balance 48,728 F1: Options vest 6/48ths on September 2, 2026 and 1/48th per month thereafter.

Filing footnotes · ownership attribution and instrument terms

F1: Options vest 6/48ths on September 2, 2026 and 1/48th per month thereafter.

Veradigm Inc.

Report date June 01, 2026 · Filed June 03, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	131,125	Reported balance After 2026-06-01 transaction · row 1 1 source row Row 1 · 2026-06-01 · Grant · Acquired 42,507 · Balance 131,125 F1: Award of Restricted Stock Units granted under the Veradigm Inc. Amended and Restated 2024 Stock Incentive Plan on June 1, 2026 (the "Grant Date"). The grant vests 100% on the first anniversary of the Grant Date.

Filing footnotes · ownership attribution and instrument terms

F1: Award of Restricted Stock Units granted under the Veradigm Inc. Amended and Restated 2024 Stock Incentive Plan on June 1, 2026 (the "Grant Date"). The grant vests 100% on the first anniversary of the Grant Date.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

AVADEL PHARMACEUTICALS PLC

Report date February 12, 2026 · Filed February 12, 2026

Section 16 reporting ended · disclosed 2026-02-12. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.59 · Expires 2035-05-13	Direct	0	Reported balance After 2026-02-12 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-02-12 · Disposition to issuer · Disposed 300,000 · Balance 0 F1: Reflects the disposition of outstanding options to purchase ordinary shares of Avadel Pharmaceuticals plc ("Issuer"), nominal value $0.01 per share ("Ordinary Shares"), in connection with the consummation of the transactions contemplated by the Transaction Agreement, dated as of October 22, 2025, as amended by Amendment No. 1 to the Transaction Agreement dated November 18, 2025, (together the "Transaction Agreement") by and between Issuer and Alkermes plc ("Parent"), including the consummation of a scheme of arrangement under Chapter 1 of Part 9 of the Companies Act 2014 of Ireland (the "Scheme") pursuant to which Parent acquired Issuer. F2: (continued) Pursuant to the Transaction Agreement, on February 12, 2026, the effective time of the Scheme (the "Effective Time"), each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option, multiplied by (b) the excess of the $21.00 over the applicable exercise price per Ordinary Share under such Option immediately prior to the Effective Time and (ii) a non-transferable contingent value right entitling the holders to a potential additional cash payment of $1.50 per share subject to such Option immediately prior to the Effective Time (without regard to vesting), contingent upon achievement of certain milestones.

Filing footnotes · ownership attribution and instrument terms

F1: Reflects the disposition of outstanding options to purchase ordinary shares of Avadel Pharmaceuticals plc ("Issuer"), nominal value $0.01 per share ("Ordinary Shares"), in connection with the consummation of the transactions contemplated by the Transaction Agreement, dated as of October 22, 2025, as amended by Amendment No. 1 to the Transaction Agreement dated November 18, 2025, (together the "Transaction Agreement") by and between Issuer and Alkermes plc ("Parent"), including the consummation of a scheme of arrangement under Chapter 1 of Part 9 of the Companies Act 2014 of Ireland (the "Scheme") pursuant to which Parent acquired Issuer.

F2: (continued) Pursuant to the Transaction Agreement, on February 12, 2026, the effective time of the Scheme (the "Effective Time"), each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option, multiplied by (b) the excess of the $21.00 over the applicable exercise price per Ordinary Share under such Option immediately prior to the Effective Time and (ii) a non-transferable contingent value right entitling the holders to a potential additional cash payment of $1.50 per share subject to such Option immediately prior to the Effective Time (without regard to vesting), contingent upon achievement of certain milestones.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 01, 2026 Filed Jun 3, 2026 16:30 UTC	Veradigm Inc. MDRX · Entity 13670	GrantCommon Stock	42,507	$0.00	$0.00	Disclosure SEC source: 0001193125-26-255563 · ownership.xml · nonDerivative · entry 1 Rodriguez Susan · CIK 0001812511 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 131,125 F1 · kind: Award of Restricted Stock Units granted under the Veradigm Inc. Amended and Restated 2024 Stock Incentive Plan on June 1, 2026 (the "Grant Date"). The grant vests 100% on the first anniversary of the Grant Date. Read SEC document
March 02, 2026 Filed Mar 4, 2026 17:25 UTC	Monopar Therapeutics MNPR · Entity 5152	GrantStock Options · Derivative	48,728	$0.00 Strike: $53.47	$0.00	Disclosure SEC source: 0001437749-26-006935 · rdgdoc.xml · derivative · entry 1 Rodriguez Susan · CIK 0001812511 · CCSO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,728 Underlying: Common Stock · 48,728 shares Expires 2036-03-02 F1 · derivative.exercise_date: Options vest 6/48ths on September 2, 2026 and 1/48th per month thereafter. Read SEC document
February 12, 2026 Filed Feb 12, 2026 17:36 UTC	AVADEL PHARMACEUTICALS PLC AVDL · Entity 65991	Disposition to issuerStock Option (Right to Buy) · Derivative	300,000	Not disclosed Strike: $9.59	Not disclosed	Disclosure SEC source: 0001104659-26-014449 · tm266121-10_4seq1.xml · derivative · entry 1 Rodriguez Susan · CIK 0001812511 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 300,000 shares Expires 2035-05-13 F1 · kind: Reflects the disposition of outstanding options to purchase ordinary shares of Avadel Pharmaceuticals plc ("Issuer"), nominal value $0.01 per share ("Ordinary Shares"), in connection with the consummation of the transactions contemplated by the Transaction Agreement, dated as of October 22, 2025, as amended by Amendment No. 1 to the Transaction Agreement dated November 18, 2025, (together the "Transaction Agreement") by and between Issuer and Alkermes plc ("Parent"), including the consummation of a scheme of arrangement under Chapter 1 of Part 9 of the Companies Act 2014 of Ireland (the "Scheme") pursuant to which Parent acquired Issuer. F2 · kind: (continued) Pursuant to the Transaction Agreement, on February 12, 2026, the effective time of the Scheme (the "Effective Time"), each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option, multiplied by (b) the excess of the $21.00 over the applicable exercise price per Ordinary Share under such Option immediately prior to the Effective Time and (ii) a non-transferable contingent value right entitling the holders to a potential additional cash payment of $1.50 per share subject to such Option immediately prior to the Effective Time (without regard to vesting), contingent upon achievement of certain milestones. F1 · price: Reflects the disposition of outstanding options to purchase ordinary shares of Avadel Pharmaceuticals plc ("Issuer"), nominal value $0.01 per share ("Ordinary Shares"), in connection with the consummation of the transactions contemplated by the Transaction Agreement, dated as of October 22, 2025, as amended by Amendment No. 1 to the Transaction Agreement dated November 18, 2025, (together the "Transaction Agreement") by and between Issuer and Alkermes plc ("Parent"), including the consummation of a scheme of arrangement under Chapter 1 of Part 9 of the Companies Act 2014 of Ireland (the "Scheme") pursuant to which Parent acquired Issuer. F2 · price: (continued) Pursuant to the Transaction Agreement, on February 12, 2026, the effective time of the Scheme (the "Effective Time"), each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option, multiplied by (b) the excess of the $21.00 over the applicable exercise price per Ordinary Share under such Option immediately prior to the Effective Time and (ii) a non-transferable contingent value right entitling the holders to a potential additional cash payment of $1.50 per share subject to such Option immediately prior to the Effective Time (without regard to vesting), contingent upon achievement of certain milestones. F1 · derivative.exercise_date: Reflects the disposition of outstanding options to purchase ordinary shares of Avadel Pharmaceuticals plc ("Issuer"), nominal value $0.01 per share ("Ordinary Shares"), in connection with the consummation of the transactions contemplated by the Transaction Agreement, dated as of October 22, 2025, as amended by Amendment No. 1 to the Transaction Agreement dated November 18, 2025, (together the "Transaction Agreement") by and between Issuer and Alkermes plc ("Parent"), including the consummation of a scheme of arrangement under Chapter 1 of Part 9 of the Companies Act 2014 of Ireland (the "Scheme") pursuant to which Parent acquired Issuer. F2 · derivative.exercise_date: (continued) Pursuant to the Transaction Agreement, on February 12, 2026, the effective time of the Scheme (the "Effective Time"), each outstanding Option (whether or not vested) was canceled and exchanged for the right to receive (i) an amount in cash (less applicable tax and any other mandatory withholdings), equal to the product of (a) the total number of Ordinary Shares subject to such Option, multiplied by (b) the excess of the $21.00 over the applicable exercise price per Ordinary Share under such Option immediately prior to the Effective Time and (ii) a non-transferable contingent value right entitling the holders to a potential additional cash payment of $1.50 per share subject to such Option immediately prior to the Effective Time (without regard to vesting), contingent upon achievement of certain milestones. Read SEC document
June 02, 2025 Filed Jun 3, 2025 19:43 UTC	Veradigm Inc. MDRX · Entity 13670	GrantCommon Stock	46,512	$4.30	$200,001.60	Disclosure SEC source: 0000950170-25-081240 · ownership.xml · nonDerivative · entry 1 Rodriguez Susan · CIK 0001812511 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 88,618 F1 · kind: Award of Restricted Stock Units granted under the Veradigm, Inc. Amended and Restated 2024 Stock Incentive Plan on June 2, 2025 (the "Grant Date"). The grant vests 100% on the first anniversary of the Grant Date. Read SEC document
May 13, 2025 Filed May 13, 2025 18:01 UTC	AVADEL PHARMACEUTICALS PLC AVDL · Entity 65991	GrantStock Option (Right to Buy) · Derivative	300,000	$0.00 Strike: $9.59	$0.00	Disclosure SEC source: 0001104659-25-047924 · tm2514868-2_4seq1.xml · derivative · entry 1 Rodriguez Susan · CIK 0001812511 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 300,000 Underlying: Ordinary Shares · 300,000 shares Expires 2035-05-13 F1 · derivative.exercise_date: The options become exercisable in four equal annual installments on each of the first four anniversaries following the 05/13/2025 grant date, subject to the Reporting Person's continued service at each such vesting date. Read SEC document
January 31, 2025 Filed Feb 4, 2025 17:27 UTC Amendment	HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133	GrantStock Option (Right to Buy) · Derivative	35,900	$0.00 Strike: $1.70	$0.00	Disclosure SEC source: 0000950170-25-013741 · ownership.xml · derivative · entry 2 Rodriguez Susan · CIK 0001812511 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,900 Underlying: Common Stock · 35,900 shares Expires 2035-01-31 F2 · derivative.exercise_date: The stock options vest and become exercisable in 12 equal monthly installments beginning one month after the date of grant. Read SEC document
January 31, 2025 Filed Feb 4, 2025 17:27 UTC Amendment	HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133	GrantCommon Stock	17,950	$0.00	$0.00	Disclosure SEC source: 0000950170-25-013741 · ownership.xml · nonDerivative · entry 1 Rodriguez Susan · CIK 0001812511 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 87,180 F1 · shares: The shares were granted as restricted stock units which vest in full on January 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock. Read SEC document
January 30, 2025 Filed Feb 3, 2025 11:33 UTC	HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133	GrantStock Option (Right to Buy) · Derivative	35,900	$1.73 Strike: $1.73	$62,107.00	Disclosure SEC source: 0000950170-25-012096 · ownership.xml · derivative · entry 2 Rodriguez Susan · CIK 0001812511 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,900 Underlying: Common Stock · 35,900 shares Expires 2035-01-30 F2 · derivative.exercise_date: The stock options vest and become exercisable in 12 equal monthly installments beginning one month after the date of grant. Read SEC document
January 30, 2025 Filed Feb 3, 2025 11:33 UTC	HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133	GrantCommon Stock	17,950	$0.00	$0.00	Disclosure SEC source: 0000950170-25-012096 · ownership.xml · nonDerivative · entry 1 Rodriguez Susan · CIK 0001812511 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 87,180 F1 · shares: The shares were granted as restricted stock units which vest in full on January 30, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock. Read SEC document
May 31, 2024 Filed Jun 20, 2024 17:00 UTC	Veradigm Inc. MDRX · Entity 13670	GrantCommon Stock	42,106	$0.00	$0.00	Disclosure SEC source: 0000950170-24-075699 · ownership.xml · nonDerivative · entry 1 Rodriguez Susan · CIK 0001812511 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,106 F1 · kind: Award of Restricted Stock Units granted under the Veradigm, Inc. 2024 Stock Incentive Plan on May 31, 2024 (the "Grant Date"). The grant vests 50% on grant Date and the other 50% on the first anniversary of the Grant Date. Read SEC document
May 21, 2024 Filed May 23, 2024 16:17 UTC	ARDELYX, INC. ARDX · Entity 4972	SaleCommon Stock	6,703	$7.81	$52,357.13	Disclosure SEC source: 0001628280-24-024949 · wk-form4_1716495453.xml · nonDerivative · entry 1 Rodriguez Susan · CIK 0001812511 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 449,092 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. F2 · balance_after: Reflects the adjusted total which includes the purchase of 3,000 shares under the Ardelyx Employee Stock Purchase Plan in February 2024. Read SEC document
February 20, 2024 Filed Feb 22, 2024 16:56 UTC	ARDELYX, INC. ARDX · Entity 4972	SaleCommon Stock	6,928	$8.75	$60,594.37	Disclosure SEC source: 0001610717-24-000082 · form4.xml · nonDerivative · entry 1 Rodriguez Susan · CIK 0001812511 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 452,795 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. Read SEC document
January 19, 2024 Filed Jan 19, 2024 21:04 UTC	HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133	GrantStock Option (Right to Buy) · Derivative	83,685	$0.00 Strike: $2.09	$0.00	Disclosure SEC source: 0001209191-24-001981 · doc4.xml · derivative · entry 2 Rodriguez Susan · CIK 0001812511 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,685 Underlying: Common Stock · 83,685 shares Expires 2034-01-19 F2 · derivative.exercise_date: The stock options vest and become exercisable in 12 equal monthly installments beginning one month after the date of grant. Read SEC document
January 19, 2024 Filed Jan 19, 2024 21:04 UTC	HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133	GrantCommon Stock	13,948	$0.00	$0.00	Disclosure SEC source: 0001209191-24-001981 · doc4.xml · nonDerivative · entry 1 Rodriguez Susan · CIK 0001812511 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,230 F1 · shares: The shares were granted as restricted stock units which vest in full on January 19, 2025. Read SEC document
January 16, 2024 Filed Jan 18, 2024 16:37 UTC	ARDELYX, INC. ARDX · Entity 4972	GrantStock Option (Right to Buy) · Derivative	145,000	$0.00 Strike: $8.78	$0.00	Disclosure SEC source: 0001628280-24-001686 · wk-form4_1705613823.xml · derivative · entry 2 Rodriguez Susan · CIK 0001812511 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 145,000 Underlying: Common Stock · 145,000 shares Expires 2034-01-16 F2 · derivative.exercise_date: The option becomes exercisable as it vests and the shares subject to the option vest in 48 successive, equal monthly installments on each monthly anniversary of January 16, 2024, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. Read SEC document
January 16, 2024 Filed Jan 18, 2024 16:37 UTC	ARDELYX, INC. ARDX · Entity 4972	GrantCommon Stock	112,750	$0.00	$0.00	Disclosure SEC source: 0001628280-24-001686 · wk-form4_1705613823.xml · nonDerivative · entry 1 Rodriguez Susan · CIK 0001812511 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 459,723 F1 · shares: Restricted stock units ("RSUs"). The Reporting Person is entitled to receive one (1) shares of Common Stock for each one (1) RSU upon the vesting thereof. Read SEC document
November 20, 2023 Filed Nov 22, 2023 17:20 UTC	ARDELYX, INC. ARDX · Entity 4972	SaleCommon Stock	4,714	$4.36	$20,563.41	Disclosure SEC source: 0001628280-23-039904 · wk-form4_1700691637.xml · nonDerivative · entry 1 Rodriguez Susan · CIK 0001812511 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 346,973 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. F2 · balance_after: Reflects the adjusted total which includes the purchase of 3,000 shares under the Ardelyx Employee Stock Purchase Plan in August 2023. Read SEC document
August 21, 2023 Filed Aug 23, 2023 16:48 UTC	ARDELYX, INC. ARDX · Entity 4972	SaleCommon Stock	4,733	$3.55	$16,810.67	Disclosure SEC source: 0001628280-23-030414 · wk-form4_1692823684.xml · nonDerivative · entry 1 Rodriguez Susan · CIK 0001812511 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 348,687 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. F2 · price: This transaction was executed in multiple trades in prices ranging from $3.511 to $3.551843, inclusive. The price reported in Column 4 above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document
May 23, 2023 Filed May 25, 2023 08:52 UTC	ARDELYX, INC. ARDX · Entity 4972	SaleCommon Stock	4,711	$3.65	$17,210.23	Disclosure SEC source: 0001104659-23-064389 · tm2316962-3_4seq1.xml · nonDerivative · entry 1 Rodriguez Susan · CIK 0001812511 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 353,420 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. F2 · balance_after: Reflects the adjusted total which includes the purchase of 3,000 shares under the Ardelyx Employee Stock Purchase Plan in February 2023. Read SEC document
February 21, 2023 Filed Mar 2, 2023 16:36 UTC	ARDELYX, INC. ARDX · Entity 4972	SaleCommon Stock	5,586	$3.00	$16,763.59	Disclosure SEC source: 0001567619-23-004210 · doc1.xml · nonDerivative · entry 1 Rodriguez Susan · CIK 0001812511 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 355,131 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. Read SEC document
January 05, 2023 Filed Jan 6, 2023 16:24 UTC	ARDELYX, INC. ARDX · Entity 4972	GrantStock Option (Right to Buy) · Derivative	351,000	$0.00 Strike: $2.73	$0.00	Disclosure SEC source: 0001567619-23-000643 · doc1.xml · derivative · entry 2 Rodriguez Susan · CIK 0001812511 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 351,000 Underlying: Common Stock · 351,000 shares Expires 2033-01-05 F2 · derivative.exercise_date: The option becomes exercisable as it vests and the shares subject to the option vest in 48 successive, equal monthly installments on each monthly anniversary of January 5, 2023, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. Read SEC document
January 05, 2023 Filed Jan 6, 2023 16:24 UTC	ARDELYX, INC. ARDX · Entity 4972	GrantCommon Stock	78,000	$0.00	$0.00	Disclosure SEC source: 0001567619-23-000643 · doc1.xml · nonDerivative · entry 1 Rodriguez Susan · CIK 0001812511 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 360,717 F1 · shares: Restricted stock units ("RSUs"). The Reporting Person is entitled to receive one (1) shares of Common Stock for each one (1) RSU upon the vesting thereof. Read SEC document
December 16, 2022 Filed Dec 20, 2022 17:21 UTC	HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133	GrantStock Option (Right to Buy) · Derivative	77,160	$0.00 Strike: $2.74	$0.00	Disclosure SEC source: 0001209191-22-062191 · doc4.xml · derivative · entry 2 Rodriguez Susan · CIK 0001812511 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,160 Underlying: Common Stock · 77,160 shares Expires 2032-12-16 F2 · derivative.exercise_date: The stock options vest and become exercisable in 12 equal monthly installments beginning one month after the date of grant. Read SEC document
December 16, 2022 Filed Dec 20, 2022 17:21 UTC	HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133	GrantCommon Stock	38,580	$0.00	$0.00	Disclosure SEC source: 0001209191-22-062191 · doc4.xml · nonDerivative · entry 1 Rodriguez Susan · CIK 0001812511 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,282 F1 · shares: The shares were granted as restricted stock units which vest in full on December 16, 2023. Read SEC document
November 22, 2022 Filed Nov 23, 2022 16:15 UTC	ARDELYX, INC. ARDX · Entity 4972	SaleCommon Stock	3,303	$1.95	$6,438.54	Disclosure SEC source: 0001567619-22-020848 · doc1.xml · nonDerivative · entry 3 Rodriguez Susan · CIK 0001812511 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 282,717 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. Read SEC document
November 22, 2022 Filed Nov 23, 2022 16:15 UTC	ARDELYX, INC. ARDX · Entity 4972	SaleCommon Stock	22	$1.95	$42.79	Disclosure SEC source: 0001567619-22-020848 · doc1.xml · nonDerivative · entry 2 Rodriguez Susan · CIK 0001812511 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 286,020 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. Read SEC document
November 22, 2022 Filed Nov 23, 2022 16:15 UTC	ARDELYX, INC. ARDX · Entity 4972	SaleCommon Stock	131	$1.94	$254.38	Disclosure SEC source: 0001567619-22-020848 · doc1.xml · nonDerivative · entry 1 Rodriguez Susan · CIK 0001812511 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 286,042 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. Read SEC document
August 22, 2022 Filed Aug 24, 2022 17:45 UTC	ARDELYX, INC. ARDX · Entity 4972	SaleCommon Stock	64	$0.98	$62.73	Disclosure SEC source: 0001567619-22-016647 · doc1.xml · nonDerivative · entry 2 Rodriguez Susan · CIK 0001812511 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 286,173 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. Read SEC document
August 22, 2022 Filed Aug 24, 2022 17:45 UTC	ARDELYX, INC. ARDX · Entity 4972	SaleCommon Stock	3,356	$0.98	$3,301.30	Disclosure SEC source: 0001567619-22-016647 · doc1.xml · nonDerivative · entry 1 Rodriguez Susan · CIK 0001812511 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 286,237 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. Read SEC document
June 06, 2022 Filed Jun 8, 2022 20:02 UTC	ARDELYX, INC. ARDX · Entity 4972	SaleCommon Stock	910	$0.64	$578.49	Disclosure SEC source: 0001567619-22-012556 · doc1.xml · nonDerivative · entry 2 Rodriguez Susan · CIK 0001812511 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 289,593 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. Read SEC document
June 06, 2022 Filed Jun 8, 2022 20:02 UTC	ARDELYX, INC. ARDX · Entity 4972	SaleCommon Stock	43,010	$0.65	$27,995.21	Disclosure SEC source: 0001567619-22-012556 · doc1.xml · nonDerivative · entry 1 Rodriguez Susan · CIK 0001812511 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 290,503 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. Read SEC document
May 20, 2022 Filed May 23, 2022 16:35 UTC	ARDELYX, INC. ARDX · Entity 4972	SaleCommon Stock	3,425	$0.67	$2,299.55	Disclosure SEC source: 0001567619-22-011522 · doc1.xml · nonDerivative · entry 1 Rodriguez Susan · CIK 0001812511 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 333,513 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. F2 · balance_after: Reflects the adjusted total which includes the purchase of 3,000 shares under the Ardelyx Employee Stock Purchase Plan on February 28, 2022. Read SEC document
February 22, 2022 Filed Feb 25, 2022 16:54 UTC	ARDELYX, INC. ARDX · Entity 4972	SaleCommon Stock	3,400	$0.67	$2,278.00	Disclosure SEC source: 0001567619-22-005657 · doc1.xml · nonDerivative · entry 1 Rodriguez Susan · CIK 0001812511 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 333,938 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. Read SEC document
January 06, 2022 Filed Jan 12, 2022 19:47 UTC	ARDELYX, INC. ARDX · Entity 4972	GrantStock Option (Right to Buy) · Derivative	195,000	$0.00 Strike: $0.99	$0.00	Disclosure SEC source: 0001567619-22-001139 · doc1.xml · derivative · entry 2 Rodriguez Susan · CIK 0001812511 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 195,000 Underlying: Common Stock · 195,000 shares Expires 2032-01-06 F2 · derivative.exercise_date: The option becomes exercisable as it vests and the shares subject to the option vest in 48 successive, equal monthly installments on each monthly anniversary of January 6, 2022, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. Read SEC document
January 06, 2022 Filed Jan 12, 2022 19:47 UTC	ARDELYX, INC. ARDX · Entity 4972	GrantCommon Stock	141,000	$0.00	$0.00	Disclosure SEC source: 0001567619-22-001139 · doc1.xml · nonDerivative · entry 1 Rodriguez Susan · CIK 0001812511 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 338,031 F1 · shares: Restricted stock units ("RSUs"). The Reporting Person is entitled to receive one (1) shares of Common Stock for each one (1) RSU upon the vesting thereof. Read SEC document
December 22, 2021 Filed Dec 23, 2021 18:58 UTC	HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133	GrantStock Option (Right to Buy) · Derivative	20,903	$0.00 Strike: $9.81	$0.00	Disclosure SEC source: 0001209191-21-071170 · doc4.xml · derivative · entry 2 Rodriguez Susan · CIK 0001812511 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,903 Underlying: Common Stock · 20,903 shares Expires 2031-12-22 F2 · derivative.exercise_date: The stock options vest and become exercisable in 12 equal monthly installments beginning one month after the date of grant. Read SEC document
December 22, 2021 Filed Dec 23, 2021 18:58 UTC	HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133	GrantCommon Stock	10,452	$0.00	$0.00	Disclosure SEC source: 0001209191-21-071170 · doc4.xml · nonDerivative · entry 1 Rodriguez Susan · CIK 0001812511 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,702 F1 · shares: The shares were granted as restricted stock units which vest in full on December 22, 2022. Read SEC document
November 22, 2021 Filed Nov 24, 2021 16:08 UTC	ARDELYX, INC. ARDX · Entity 4972	SaleCommon Stock	643	$0.99	$637.79	Disclosure SEC source: 0001567619-21-021164 · doc1.xml · nonDerivative · entry 1 Rodriguez Susan · CIK 0001812511 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 197,030 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. Read SEC document
October 08, 2021 Filed Oct 29, 2021 19:56 UTC	ARDELYX, INC. ARDX · Entity 4972	GrantCommon Stock	150,000	$0.00	$0.00	Disclosure SEC source: 0001567619-21-019031 · doc1.xml · nonDerivative · entry 1 Rodriguez Susan · CIK 0001812511 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 197,673 F1 · shares: Restricted stock units ("RSUs"). The Reporting Person is entitled to receive one (1) shares of Common Stock for each one (1) RSU upon the vesting thereof. F2 · balance_after: Reflects the adjusted total which includes the purchase of 3,000 shares under the Ardelyx Employee Stock Purchase Plan on August 31, 2021. Read SEC document
August 20, 2021 Filed Aug 24, 2021 18:07 UTC	ARDELYX, INC. ARDX · Entity 4972	SaleCommon Stock	630	$1.32	$831.60	Disclosure SEC source: 0001567619-21-016286 · doc1.xml · nonDerivative · entry 1 Rodriguez Susan · CIK 0001812511 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,673 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. Read SEC document
May 20, 2021 Filed May 21, 2021 16:49 UTC	ARDELYX, INC. ARDX · Entity 4972	SaleCommon Stock	611	$7.09	$4,330.65	Disclosure SEC source: 0001567619-21-010924 · doc1.xml · nonDerivative · entry 1 Rodriguez Susan · CIK 0001812511 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,303 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. Read SEC document
February 22, 2021 Filed Feb 24, 2021 16:40 UTC	ARDELYX, INC. ARDX · Entity 4972	SaleCommon Stock	611	$6.88	$4,205.21	Disclosure SEC source: 0001567619-21-004775 · doc1.xml · nonDerivative · entry 1 Rodriguez Susan · CIK 0001812511 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,914 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. Read SEC document
January 05, 2021 Filed Jan 7, 2021 19:11 UTC	ARDELYX, INC. ARDX · Entity 4972	GrantStock Option (Right to Buy) · Derivative	146,755	$0.00 Strike: $6.35	$0.00	Disclosure SEC source: 0001567619-21-000764 · doc1.xml · derivative · entry 2 Rodriguez Susan · CIK 0001812511 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,755 Underlying: Common Stock · 146,755 shares Expires 2031-01-05 F2 · derivative.exercise_date: The option becomes exercisable as it vests and the shares subject to the option vest in 48 successive, equal monthly installments on each monthly anniversary of January 5, 2021, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. Read SEC document
January 05, 2021 Filed Jan 7, 2021 19:11 UTC	ARDELYX, INC. ARDX · Entity 4972	GrantCommon Stock	32,612	$0.00	$0.00	Disclosure SEC source: 0001567619-21-000764 · doc1.xml · nonDerivative · entry 1 Rodriguez Susan · CIK 0001812511 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,525 F1 · shares: Restricted stock units ("RSUs"). The Reporting Person is entitled to receive one (1) shares of Common Stock for each one (1) RSU upon the vesting thereof. Read SEC document
September 16, 2020 Filed Sep 17, 2020 18:35 UTC	ARDELYX, INC. ARDX · Entity 4972	SaleCommon Stock	6,087	$6.11	$37,164.18	Disclosure SEC source: 0001567619-20-016851 · doc1.xml · nonDerivative · entry 1 Rodriguez Susan · CIK 0001812511 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,913 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. F2 · price: This transaction was executed in multiple trades in prices ranging from $6.05 to $6.1611, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document
May 18, 2020 Filed May 20, 2020 17:47 UTC	ARDELYX, INC. ARDX · Entity 4972	GrantStock Option (Right to Buy) · Derivative	232,750	$0.00 Strike: $7.70	$0.00	Disclosure SEC source: 0001567619-20-010851 · doc1.xml · derivative · entry 2 Rodriguez Susan · CIK 0001812511 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 232,750 Underlying: Common Stock · 232,750 shares Expires 2030-05-18 F2 · derivative.exercise_date: Twenty Five Percent (25%) of the shares subject to the option vest on May 18, 2021 and the remaining shares subject to the option vest in 36 successive, equal monthly installments thereafter, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. Read SEC document
May 18, 2020 Filed May 20, 2020 17:47 UTC	ARDELYX, INC. ARDX · Entity 4972	GrantCommon Stock	20,000	$0.00	$0.00	Disclosure SEC source: 0001567619-20-010851 · doc1.xml · nonDerivative · entry 1 Rodriguez Susan · CIK 0001812511 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 F1 · shares: Restricted stock units ("RSUs"). The Reporting Person is entitled to receive one (1) share of Common Stock for each one (1) RSU upon the vesting thereof. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.